Neurocognitive effects of androgen deprivation therapy and new hormonal agents in a sample of patients with metastatic prostate cancer

被引：0
作者：
Andreas Ihrig
Pascal Marino Pernt
Stefanie Zschäbitz
Johannes Huber
Hans-Christoph Friederich
Till J. Bugaj
Imad Maatouk
机构：
[1] University Hospital Heidelberg,Division of Psycho
[2] National Centre for Tumor Diseases (NCT),Oncology, Department of General Internal Medicine and Psychosomatics
[3] University Hospital Heidelberg,Department of Medical Oncology
[4] Philipps-University Marburg,Department of Urology
[5] Julius-Maximilian University Würzburg,Section of Psychosomatic Medicine, Psychotherapy and Psycho
来源：
International Urology and Nephrology | 2023年 / 55卷
关键词：
Metastatic prostate cancer; Hormonal agents; Androgen deprivation therapy; Neurocognitive effects;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：2733 / 2739
页数：6
相关论文
共 50 条
  • [21] Age-dependent overall survival benefit of androgen deprivation therapy for metastatic prostate cancer
    Keating, Matthew J.
    Giscombe, Lisa
    Tannous, Toufic
    Reddy, Nishitha
    Mukkamalla, Shiva Kumar R.
    DeSouza, Andre
    Rathore, Ritesh
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2019, 25 (08) : 1927 - 1932
  • [22] Adverse effects of androgen deprivation therapy in patients with prostate cancer: focus on metabolic complications
    Vasileios Tzortzis
    Michael Samarinas
    Ioannis Zachos
    Athanasios Oeconomou
    Louis L. Pisters
    Alexandra Bargiota
    Hormones, 2017, 16 : 115 - 123
  • [23] Androgen deprivation therapy and the risk of tenosynovitis in prostate cancer patients
    Liu, Jui-Ming
    Liu, Dai-Wei
    Chuang, Heng-Chang
    Wu, Chun-Te
    Lin, Chien-Yu
    Hsu, Ren-Jun
    INTERNATIONAL UROLOGY AND NEPHROLOGY, 2019, 51 (07) : 1113 - 1119
  • [24] miRNAs and androgen deprivation therapy for prostate cancer
    Konoshenko, Maria Yu
    Bryzgunova, Olga E.
    Laktionov, Pavel P.
    BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 2021, 1876 (02):
  • [25] Advances with androgen deprivation therapy for prostate cancer
    Yu, Eun-mi
    Aragon-Ching, Jeanny B.
    EXPERT OPINION ON PHARMACOTHERAPY, 2022, 23 (09) : 1015 - 1033
  • [26] Complications of androgen deprivation therapy in prostate cancer
    Schwandt, Anita
    Garcia, Jorge A.
    CURRENT OPINION IN UROLOGY, 2009, 19 (03) : 322 - 326
  • [27] Relationship between body composition and hormone sensitivity for androgen deprivation therapy in patients with metastatic prostate cancer
    Kashiwagi, Eiji
    Shiota, Masaki
    Masaoka, Hiroyuki
    Imada, Kenjiro
    Monji, Keisuke
    Takeuchi, Ario
    Inokuchi, Junichi
    Tatsugami, Katsunori
    Eto, Masatoshi
    PROSTATE INTERNATIONAL, 2020, 8 (01) : 22 - 26
  • [28] Adverse effects of androgen-deprivation therapy in prostate cancer and their management
    Rhee, Handoo
    Gunter, Jennifer H.
    Heathcote, Peter
    Ho, Ken
    Stricker, Phillip
    Corcoran, Niall M.
    Nelson, Colleen C.
    BJU INTERNATIONAL, 2015, 115 : 3 - 13
  • [29] Perspectives on the Cardiovascular and Metabolic Effects of Androgen Deprivation Therapy in Prostate Cancer
    Daniel Sentana-Lledo
    Alicia K. Morgans
    Current Oncology Reports, 2024, 26 : 299 - 306
  • [30] Androgen and prostate cancer: the role of primary androgen deprivation therapy in localized prostate cancer
    Namiki, Mikio
    Kitagawa, Yasuhide
    Mizokami, Atsushi
    Koh, Eitetsu
    JOURNAL OF MENS HEALTH, 2008, 5 (04) : 333 - 341
12345